Heleen Scheerens

6.5k total citations · 3 hit papers
40 papers, 4.9k citations indexed

About

Heleen Scheerens is a scholar working on Physiology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Heleen Scheerens has authored 40 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Physiology, 16 papers in Immunology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Heleen Scheerens's work include Asthma and respiratory diseases (23 papers), Allergic Rhinitis and Sensitization (9 papers) and Respiratory and Cough-Related Research (8 papers). Heleen Scheerens is often cited by papers focused on Asthma and respiratory diseases (23 papers), Allergic Rhinitis and Sensitization (9 papers) and Respiratory and Cough-Related Research (8 papers). Heleen Scheerens collaborates with scholars based in United States, Netherlands and Canada. Heleen Scheerens's co-authors include John G. Matthews, Joseph R. Arron, D Rennick, Phillip E. Korenblat, Lawren C. Wu, Jeffrey M. Harris, Sofia Mosesova, Nicola A. Hanania, Jonathan Corren and Sean P. Bohen and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Blood.

In The Last Decade

Heleen Scheerens

38 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6

2006 1.2k citations Heleen Scheerens, D Rennick et al. profile →
Lebrikizumab Treatment in Adults with Asthma

2011 1.1k citations Jonathan Corren, Robert F. Lemanske et al. New England Journal of Medicine profile →
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

2006 517 citations Zhengying Pan, Heleen Scheerens et al. ChemMedChem profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heleen Scheerens United States	25	2.2k	1.9k	1.1k	812	615	40	4.9k
Martijn C. Nawijn Netherlands	34	1.5k 0.7×	1.1k 0.6×	894 0.8×	1.6k 1.9×	495 0.8×	117	4.4k
Paul A. Monach United States	38	1.7k 0.8×	653 0.3×	2.1k 2.0×	1.3k 1.6×	352 0.6×	129	5.2k
Bernd Engelmann Germany	32	1.6k 0.7×	533 0.3×	697 0.6×	1.6k 2.0×	292 0.5×	69	5.7k
Raffaele De Palma Italy	38	2.2k 1.0×	534 0.3×	505 0.5×	1.3k 1.6×	197 0.3×	118	4.9k
A. McGarry Houghton United States	32	2.3k 1.0×	479 0.2×	1.8k 1.7×	1.4k 1.8×	210 0.3×	67	5.7k
Giuseppe A. Andres United States	42	1.3k 0.6×	377 0.2×	735 0.7×	886 1.1×	572 0.9×	138	4.7k
Rafał Pawliński United States	40	1.8k 0.8×	490 0.3×	544 0.5×	2.2k 2.7×	177 0.3×	103	6.7k
Frank H. Valone United States	37	2.0k 0.9×	492 0.3×	1.3k 1.2×	1.8k 2.2×	187 0.3×	129	6.2k
L. Vijaya Mohan Rao United States	45	1.0k 0.5×	374 0.2×	882 0.8×	1.7k 2.1×	420 0.7×	181	7.5k
Zhenyu Li China	35	1.0k 0.5×	316 0.2×	551 0.5×	1.5k 1.9×	386 0.6×	119	4.7k

Countries citing papers authored by Heleen Scheerens

Since Specialization

Citations

This map shows the geographic impact of Heleen Scheerens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heleen Scheerens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heleen Scheerens more than expected).

Fields of papers citing papers by Heleen Scheerens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heleen Scheerens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heleen Scheerens. The network helps show where Heleen Scheerens may publish in the future.

Co-authorship network of co-authors of Heleen Scheerens

This figure shows the co-authorship network connecting the top 25 collaborators of Heleen Scheerens. A scholar is included among the top collaborators of Heleen Scheerens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heleen Scheerens. Heleen Scheerens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scheerens, Heleen, Zachary Boyd, Vivek P. Gupta, et al.. (2017). Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch. Clinical and Translational Science. 10(2). 84–92. 81 indexed citations

Harris, Jeffrey M., Romeo Maciuca, Mary S. Bradley, et al.. (2016). A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respiratory Research. 17(1). 29–29. 73 indexed citations

Wu, Lawren C. & Heleen Scheerens. (2014). Targeting IgE production in mice and humans. Current Opinion in Immunology. 31. 8–15. 44 indexed citations

Arron, Joseph R., Heleen Scheerens, & John G. Matthews. (2013). Redefining Approaches to Asthma. Advances in pharmacology. 66. 1–49. 26 indexed citations

Noonan, Michael, Phillip E. Korenblat, Sofia Mosesova, et al.. (2013). Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. Journal of Allergy and Clinical Immunology. 132(3). 567–574.e12. 140 indexed citations

Arron, Joseph R., David F. Choy, Heleen Scheerens, & John G. Matthews. (2013). Noninvasive Biomarkers That Predict Treatment Benefit from Biologic Therapies in Asthma. Annals of the American Thoracic Society. 10(Supplement_1). S206–S213. 44 indexed citations

Corren, Jonathan, Robert F. Lemanske, Nicola A. Hanania, et al.. (2011). Lebrikizumab Treatment in Adults with Asthma. New England Journal of Medicine. 365(12). 1088–1098. 1097 indexed citations breakdown →

Scheerens, Heleen, Zheng Su, Bryan Irving, et al.. (2011). MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments. Arthritis Research & Therapy. 13(5). R177–R177. 17 indexed citations

Zheng, Yanan, Heleen Scheerens, John C. Davis, et al.. (2010). Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study. Clinical Pharmacology & Therapeutics. 89(2). 283–290. 34 indexed citations

10.

Pan, Zhengying, Heleen Scheerens, Shyr‐Jiann Li, et al.. (2006). Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase. ChemMedChem. 2(1). 58–61. 517 indexed citations breakdown →

11.

Sperandio, David, Vincent W.‐F. Tai, Julia Lohman, et al.. (2006). Novel, potent, selective, and orally bioavailable human βII-tryptase inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(15). 4085–4089. 9 indexed citations

12.

Dalrymple, Stacie A., et al.. (2005). A Selective Small Molecule Factor VIIa Inhibitor, CRA-027483, Suppresses Acute Inflammation in Mice.. Blood. 106(11). 3089–3089. 1 indexed citations

13.

Al‐Rasheed, Abdulaziz, Heleen Scheerens, Apurva K. Srivastava, D Rennick, & Dimitris N. Tatakis. (2004). Accelerated alveolar bone loss in mice lacking interleukin‐10: late onset. Journal of Periodontal Research. 39(3). 194–198. 31 indexed citations

14.

Scheerens, Heleen, Edith M. Hessel, René de Waal Malefyt, Michael W. Leach, & D Rennick. (2001). Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL-10/ mice and Rag-2/ mice reconstituted with CD4+CD45RBhigh T cells. European Journal of Immunology. 31(5). 1465–1474. 91 indexed citations

15.

Scheerens, Heleen, et al.. (1999). Long-term Topical Exposure to Toluene Diisocyanate in Mice Leads to Antibody Production and In Vivo Airway Hyperresponsiveness Three Hours after Intranasal Challenge. American Journal of Respiratory and Critical Care Medicine. 159(4). 1074–1080. 61 indexed citations

16.

Scheerens, Heleen, et al.. (1996). Toluene Diisocyanate-Induced In Vitro Tracheal Hyperreactivity in the Mouse. American Journal of Respiratory and Critical Care Medicine. 154(4). 858–865. 51 indexed citations

17.

Scheerens, Heleen, et al.. (1996). The involvement of sensory neuropeptides in toluene diisocyanate‐induced tracheal hyperreactivity in the mouse airways. British Journal of Pharmacology. 119(8). 1665–1671. 40 indexed citations

18.

Goeptar, Arnold R., Heleen Scheerens, & Nico Vermeulen. (1995). Oxygen and Xenobiotic Reductase Activities of Cytochrome P450. Critical Reviews in Toxicology. 25(1). 25–65. 211 indexed citations

19.

Goeptar, Arnold R., et al.. (1994). Cytotoxicity of mitomycin C and adriamycin in freshly isolated rat hepatocytes: the role of cytochrome P450.. PubMed. 54(9). 2411–8. 37 indexed citations

20.

Scheerens, Heleen, et al.. (1992). A simple and rapid in vitro test system for the screening of histamine H3 ligands.. PubMed. 14(10). 747–51. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact